Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | MIF | P14174 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2781192 | 0.94 | L3MBTL1 (0.65) | L3MBTL1TDP1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL10394888 | 0.92 | L3MBTL1 (0.62) | L3MBTL1TDP1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2001469 | 0.89 | L3MBTL1 (0.58) | L3MBTL1TDP1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL29742293 | 0.87 | L3MBTL1 (0.70) | L3MBTL1TDP1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL29742239 | 0.87 | L3MBTL1 (0.77) | L3MBTL1TDP1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1592409 | 0.84 | CA12 (0.68) | L3MBTL1TDP1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL11152823 | 0.83 | L3MBTL1 (0.61) | L3MBTL1TDP1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL9907038 | 0.81 | L3MBTL1 (0.63) | L3MBTL1TDP1LMNASMN1; SMN2ALDH1A1 | |
| 1-Methoxy-2-Butoxybenzene SCHEMBL364856 | 0.81 | L3MBTL1 (0.63) | L3MBTL1TDP1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1545294 | 0.81 | L3MBTL1 (0.63) | L3MBTL1TDP1LMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615890-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER-LAMBERT COMPANY (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089903-A9 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER LAMBERT CO (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089903-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | disclosed |
| US-4590291-A | Thrombin inhibitory new dihydroxybenzene ether derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1986-05-20 | — | — | US | disclosed |
| EP-0054132-B1 | PYRIMIDONES, THEIR PREPARATION AND MEDICINES CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1984-10-10 | — | — | EP | disclosed |
| US-4379788-A | HYPOTENSIVES, ANTIARRHYTHMIA, B-BLOCKERS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-04-12 | — | — | US | disclosed |
| EP-0068250-A1 | Dioxybenzene ether derivatives, pharmaceutical compositions containing them, process for the preparation thereof and their use | BAYER AG (DE) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | REN, ACE, HPN | L3MBTL1 4854/4885TDP1 4229/4885LMNA 1866/4885 |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | L3MBTL1 4859/4885TDP1 4579/4885LMNA 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.